This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause a buildup of fluid inside the eye and cause increased Intraocular Pressure (IOP). REGN22530 attaches to this protein and stops it from working which may allow more fluid to drain out of the eye and decrease the pressure. The study is looking at: * What side effects REGN22530 might cause * How much REGN22530 is in the blood and eye fluid at different times * If the body has any reactions to REGN22530 (which may cause REGN22530 to not work as well) * How the body and eye pressure respond after having REGN22530, which can help researchers understand why REGN22530 works better in some people than others * How well REGN22530 works
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
271
Administered per the protocol
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Part A and B
Time frame: Up to week 16
Change from baseline in mean diurnal IOP in the study eye
Part C
Time frame: At day 85
Concentrations of REGN22530 in serum
Time frame: Up to week 24
Occurrence of Anti-Drug Antibodies (ADAs) to REGN22530 in serum
Time frame: Up to week 24
Magnitude of ADAs to REGN22530 in serum
Time frame: Up to week 24
Occurrence of TEAEs
Part C
Time frame: Up to week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.